Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NOS3 | P29474 | 3/20 | 0.49 |
| ▸ | NOS1 | P29475 | 3/20 | 0.49 |
| ▸ | NOS2 | P35228 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.46 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL420575 | 0.93 | NOS3 (0.56) | KDM4ENOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL250790 | 0.91 | NOS3 (0.52) | KDM4EL3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL5824197 | 0.86 | KDM4E (0.54) | KDM4EL3MBTL1ALDH1A1HRH3TSHR | |
| SCHEMBL220207 | 0.83 | NPC1 (0.53) | NOS3NOS1NOS2KMT2ASRC | |
| SCHEMBL6583442 | 0.79 | HTR7 (0.42) | KDM4ENOS3NOS1NOS2KCNH2 | |
| SCHEMBL221772 | 0.76 | HTR7 (0.61) | NOS3NOS1NOS2 | |
| SCHEMBL6302805 | 0.73 | ALDH1A1 (0.51) | NOS3NOS1NOS2ALDH1A1HRH3 | |
| SCHEMBL8096602 | 0.73 | NOS3 (0.60) | NOS3NOS1NOS2HRH3KCNH2 | |
| SCHEMBL252497 | 0.73 | NOS3 (0.66) | KDM4ENOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL6582950 | 0.73 | NOS3 (0.62) | KDM4ENOS3NOS1NOS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| WO-2018033639-A1 | LACTONE INTERMEDIATES OF NICOTINAMIDE RIBOSIDE AND NICOTINATE RIBOSIDE | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-02-22 | — | — | WO | disclosed |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20150175645-A1 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | GLAXOSMITHKLINE LLC (US) | 2015-06-25 | — | — | US | disclosed |
| EP-2805719-A1 | Nicotinamide riboside and analogues thereof | Glaxosmithkline LLC (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2006094246-A2 | N-ARYLMETHYL BENZAMIDE SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094237-A2 | ACRIDINE AND QUINOLINE DERVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-0958282-B1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PROD INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | PFIZER INC. | 2001-07-12 | — | — | US | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NNT, CS, ME2 | KDM4E 3880/4885L3MBTL1 2667/4885NOS3 1327/4885 |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | NNT, HADHB, NAMPT | KDM4E 4767/4885L3MBTL1 4054/4885NOS3 2462/4885 |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | KDM4E 1582/4885L3MBTL1 3698/4885NOS3 157/4885 |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | NOS1, PTGS1, NOS2 | KDM4E 2152/4885L3MBTL1 1748/4885NOS3 4/4885 |
| US-20150175645-A1 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | SIRT1, NAMPT, SIRT2 | KDM4E 2983/4885L3MBTL1 3101/4885NOS3 243/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | KDM4E 939/4885L3MBTL1 2431/4885NOS3 2/4885 |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | NNT, HADHB, NAMPT | KDM4E 4767/4885L3MBTL1 4054/4885NOS3 2462/4885 |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | NNT, CS, ME2 | KDM4E 3880/4885L3MBTL1 2667/4885NOS3 1327/4885 |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | GRIN2C, GRIN2A, CNR2 | KDM4E 4095/4885L3MBTL1 3214/4885NOS3 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.